Therapeutic Area

Asthma

Therapeutic area intelligence for Asthma with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 4
Catalysts: 0
Companies: 2

Companies

Amgen →

AstraZeneca →

Assets

Budget →

Respiratory →

Tezepelumab →

Recent signals(4)

ClinicalJune 21, 2026

Amgen's AMG 691 Phase 1 Study Targets Safety in Asthma Patients

Amgen is conducting Phase 1 study to evaluate the safety and tolerability of AMG 691 in healthy participants and those with mild-to-moderate asthma.

StrategyJune 21, 2026

Budget Impact of Single-Inhaler Triple Therapy for Asthma in Saudi Arabia

The study evaluates the financial implications of introducing FF/UMEC/VI therapy for asthma in Saudi Arabia.

ClinicalJune 18, 2026

EVOLVE Study to Assess Real-World Effectiveness of Tezepelumab in Severe Asthma in Greece

The EVOLVE study will evaluate the real-world effectiveness of tezepelumab in uncontrolled severe asthma over two years in Greece.

RegulatoryJune 1, 2026

Breztri Gains US Approval as First Triple Therapy for Asthma

Breztri has been approved in the US as the first and only triple therapy for asthma in patients aged 12 and older, based on positive Phase III trial results.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Asthma →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.